Ligand Pharmaceuticals | LGND - Cash And Equivalent


Ligand Pharmaceuticals reported $115.08M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agenus USD 35M 32M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Baxter International USD 2.02B 51M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Enviri Corporation USD 105.7M 2.03M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 263.14M 99.44M Mar/2026